Aclaris Therapeutics Reveals Interim Results From the First-in-human Phase 1a Single and Multiple Ascending Dose Trial of ATI-052
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052Trial Results Support Potential for Extended Dosing of up to Every
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052
- Trial Results Support Potential for Extended Dosing of up to Every Three Months
- Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 -